News

China's new Alzheimer's drug completes phase 3 clinical trial

News

SHANGHAI - A Chinese research group on Tuesday announced progress in developing a drug to treat Alzheimer's disease.


GV-971 was developed by Ocean University of China, Shanghai Institute of Materia Medica under Chinese Academy of Sciences and Green Valley Pharmaceutical Co., Ltd, after a 21-year study.


A phase three clinical trial is the last test before reaching the market.In the trial, participants took 450 mg GV-971 orally twice a day for 36 weeks, which proved effective in improving cognition.


Extracted from brown algae, the drug is targeted at patients with mild-to-moderate Alzheimer's. 

Independent animal experiments also showed that it can regulate the immune system, reduce neuro-inflammation and improve cognition.


Alzheimer's disease is an irreversible, progressive brain disorder that slowly destroys memory, thinking skills, and the ability to carry out simple tasks. The disease affects about 48 million people worldwide, and the number is expected to increase with the aging population. There is no effective cure.


The drug opens a new avenue for treatment and provides patients with a new solution and hope, said lead researcher Geng Meiyu.

From: Chinadaily news  July 17th, 2018

0 Comments
Leave a Comment
Your email address will not be published. Required fields are marked *
Name *          Enter your Name
Email *          Enter your Email
Submit Comment
Concact Us Now
Headquarter:Room 806, D&D Fortune Center, No. 182-6 Haier Road, Qingdao 266061, China
You can trust us
We are a professional Manufacturer in China, and we are constantly innovating so that our customers can have better products and services.
© 2018 Gobalsir Inc. RELATED ARTICLES   SiteMap.html SiteMap.xml
Marketing Support by Globalsir